Prediction of outcome in melanoma has proved elusive. Morphologic standards (thickness) and lymph node status remain the best predictors, in spite of extensive efforts to find tissue bio-markers. Recently, the addition of sentinel node biopsy has resulted in less morbid assessment of metastasis. Sentinel node biopsy is negative in 75-90% of the cases (thus the procedure was potentially unnecessary) and as many as 25% of the negatives will ultimately be upstaged. This data suggests there is a need for a better method of assessing the likelihood of metastasis at the time of primary diagnosis. The efforts to discover molecular methods for assessment of early stage primary disease have been complicated and slowed by the difficulty in obtaining tissue from small tumors. This proposal is a translational effort to directly address these problems by discovery of a small series of bio-markers, that when measured accurately, tightly correlate to metastasis. We propose to discover this marker set using a novel in situ method of quantitative analysis of tissue sections (called AQUA) which has detected relationships between expression and outcome that are not detectable using the traditional pathologist-based method. Specifically, we will use a tissue microarray with over 500 melanomas with long term follow-up as a method to discover the key set of prognostic markers. We have already completed a series of markers and have over 10 that show prognostic value in primary tumors. Once we have constructed and optimized combined set of markers, we will then test them on a newly constructed tissue microarray which represents primary tumors from a recent Yale-based series of cases, all of which have sentinel node biopsy results and recurrence/outcome data in our database. Once we have optimized and validated the marker set on the new array, we will test it on prospectively collected, intervening, whole histologic sections, from cases seen in the Yale Dermatopathology labs. Many of these cases will have sentinel node biopsies within a month or two of the primary diagnosis, providing a near term intermediate endpoint to test the value of our assay. We anticipate this method could provide a future replacement for sentinel node biopsy that is both less morbid and more accurate.
| Viray, Hollis; Coulter, Madeline; Li, Kevin et al. (2014) Automated objective determination of percentage of malignant nuclei for mutation testing. Appl Immunohistochem Mol Morphol 22:363-71 |
| How, Joan; Brown, Jason R; Saylor, Sasha et al. (2014) Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. Histochem Cell Biol 142:195-204 |
| Brown, Jason R; Wimberly, Hallie; Lannin, Donald R et al. (2014) Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 20:5995-6005 |
| Rimm, David; Schalper, Kurt; Pusztai, Lajos (2014) Unvalidated antibodies and misleading results. Breast Cancer Res Treat 147:457-8 |
| Rothberg, Bonnie E Gould; Rimm, David L (2014) Construction and analysis of multiparameter prognostic models for melanoma outcome. Methods Mol Biol 1102:227-58 |
| Viray, Hollis; Bradley, William R; Schalper, Kurt A et al. (2013) Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med 137:1063-73 |
| Velcheti, Vamsidhar; Rimm, David L; Schalper, Kurt A (2013) Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 8:803-5 |
| Hanna, Jason A; Wimberly, Hallie; Kumar, Salil et al. (2012) Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques 52:235-45 |
| Hanna, Jason A; Hahn, Lewis; Agarwal, Seema et al. (2012) In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab Invest 92:1390-7 |
| Dolled-Filhart, Marisa; Gustavson, Mark; Camp, Robert L et al. (2010) Automated analysis of tissue microarrays. Methods Mol Biol 664:151-62 |
Showing the most recent 10 out of 22 publications
